This is a preview of subscription content, log in via an institution to check access.
References
Bonafede MM, et al. Cost-Effectiveness of Efavirenz Compared with Generic Nevirapine in Hiv Patients Initiating First-Line Treatment in the United States. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PIN70, 18 May 2013.
Juday T, et al. Cost-Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Compared with Efavirenz/Emtricitabine/Tenofovir as First-Line Hiv Antiretroviral Therapy in the Adult Population in the United States. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PIN72, 18 May 2013.
Despiegel N, et al. Economic Modeling in Hiv for Maraviroc in Treatment-Naive Patients in the United States - Results from the Aramis-Mvc 2012 Model. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PIN80, 18 May 2013.
Additional information
* The study received financial support from Bristol-Myers Squibb, US.
** The study received financial support from Pfizer, US.
Rights and permissions
About this article
Cite this article
Searching for `best value' first-line HIV antiretrovirals. PharmacoEcon Outcomes News 680, 10 (2013). https://doi.org/10.1007/s40274-013-0475-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0475-6